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Antibiotics	in	
trachoma	control
Trachoma is caused by repeated ocular 
infection with the bacterium Chlamydia 
trachomatis. It is, therefore, logical that 
anti-chlamydial antibiotics have become 
a key component of the SAFE strategy. 
Tetracycline is an effective anti-chlamydial 
agent. However, because of its effect 
on growing teeth, oral tetracycline is not 
recommended for children less than 12 
years of age, or for pregnant or breast-
feeding women. Tetracycline eye ointment 
is safer than oral tetracycline, but is difficult 
and unpleasant to apply: if treatment is 
unsupervised, compliance for a full six-week 
course is thought to be poor. Fortunately, 
during the 1990s, it was shown that ocular 
C. trachomatis infections can success-
fully be cleared with a single oral dose 
of the antibiotic azithromycin,1 and that 
treatment of whole communities is practical, 
acceptable to the community, effective,2 
and results in a low incidence of adverse 
reactions.3 An operational comparison 
suggested that directly-observed single-
dose azithromycin is more effective at 
achieving clinical cure of active trachoma 
than six weeks’ unsupervised tetracycline 
ointment.4 The main limitation to the use of 
azithromycin for trachoma control is its cost, 
which is high if the drug is not donated. 
In 1999, when this journal last 
published a full issue on trachoma, azithro-
mycin’s manufacturer (Pfizer Inc.) was 
establishing donation programmes in 
five trachoma-endemic countries.5 The 
scheme has now been expanded to 
include a number of additional countries. 
Several other developments in the last five 
years have had an impact on the way in 
which recipient programmes use donated 
azithromycin to control trachoma.
Who	should	be	given	
azithromycin?
Trachoma is a community-level problem, 
and must be managed at the community 
level: treatment of individuals presenting 
to health facilities will have little impact 
on transmission. Previously, therefore, 
the World Health Organization (WHO) 
recommended community-level assessment 
of the prevalence of TF and TI (signs of 
active disease) to determine whether or not 
community-based distribution of antibiotics 
was warranted.6 Mass distribution of antibi-
otics (treatment of all members of all families 
in the community) was recommended if (a) 
the prevalence of TF in children was 20 per 
cent or greater, or (b) the prevalence of TI in 
children was 5 per cent or greater. Targeted 
distribution (treatment of all members of any 
family in which one or more family members 
had TF or TI) was recommended where the 
prevalence of TF in children was 5 per cent 
or greater, but less than 20 per cent.6 
Three important changes have recently 
been made to these guidelines.
1  Recognising that, to achieve global 
elimination of trachoma, large popula-
tions will need to be given antibiotics, 
WHO suggest that initial assessment 
of the prevalence of disease (and 
determination of the need for antibiotic 
distribution) be made at the district 
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Table 1. Current WHO recommendations for antibiotic treatment of trachoma
 1 Determine the district-level prevalence of tF in 1 to 9 year-old children.
 If this is 10 per cent or more, conduct mass treatment with antibiotic throughout the district.
 If this is less than10 per cent, conduct assessment at the community level in areas 
 of known disease.
 2 If assessment at the community level is undertaken:
 In communities in which the prevalence of TF in 1 to 9 year-old children is 10 per cent 
 or more, conduct mass treatment with antibiotic.
 In communities in which the prevalence of TF in 1 to 9 year-old children is 5 per cent 
 or more, but less than 10 per cent, targeted treatment should be considered.
 In communities in which the prevalence of TF in 1 to 9 year-old children is less than 
 5 per cent, antibiotic distribution is not recommended.
a child receiving 
oral azithromycin. 
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‘in Ghana, trained community health volunteers 
have managed and dispensed azithromycin’
level, rather than the community 
level. Treatment of whole districts 
should help to minimise re-infection 
through contact between people 
from treated communities and those 
from untreated communities.
2 Because TF is a more reliable sign of 
trachoma than TI, determination of the 
need for antibiotic distribution should 
be based only on the prevalence of TF.
3 The prevalence of TF in children at or 
above which mass antibiotic treatment 
is recommended has been lowered 
from 20 per cent to 10 per cent. 
Targeted treatment is therefore only 
considered when the prevalence of TF 
in children is less than 10 per cent. 
This is good for programmes, since 
screening communities for cases 
of active trachoma is very labour-
intensive. In hypoendemic areas, 
family treatment (identification and 
treatment of families in which there 
are one or more members with TF or 
TI) is an effective way to maximise 
the proportion of C. trachomatis – 
infected people given antibiotics.7 
Pregnant	women	and	infants
At first, azithromycin being distributed 
for trachoma control was withheld from 
pregnant women because there were no 
data demonstrating that it was safe in 
this group.5 A randomised controlled trial 
of the effect (on pregnancy outcome) of 
presumptive treatment of mothers for 
sexually transmitted diseases has recently 
provided useful data. The study compared 
babies born to mothers given three or four 
different STD treatments, including 1g 
azithromycin, during pregnancy, with those 
not given any of these drugs; neonatal 
death, low birth weight, pre-term delivery 
and infant ophthalmia were all signifi-
cantly less common in the treated group.8 
National programmes should consider 
this evidence, which seems to support 
the use of azithromycin in pregnancy.
Recent research has highlighted the 
importance of young children as reservoirs 
of infection, particularly in areas with a lower 
prevalence of trachoma.7 9 Antibiotic distri-
bution teams should offer azithromycin to 
all individuals over the age of six months 
in eligible communities, and pay particular 
attention to ensuring they achieve high 
coverage in children below ten years of 
age. Tetracycline eye ointment should be 
given to children below six months of age, 
and offered to older individuals who refuse 
or cannot receive azithromycin. Overall 
coverage should be as high as possible, 
but treatment of 80% of the resident 
population should be the minimum target.10
Who	should	distribute	
azithromycin?
In most trachoma-endemic areas, there 
are insufficient trained medical and nursing 
personnel. A pilot study in Ghana showed 
that trained community health volunteers 
could safely manage and dispense azithro-
mycin to both children and adults.11 This 
cadre now routinely assists in antibiotic 
distribution throughout National Trachoma 
Control Programme intervention areas in 
Ghana. Literate volunteers from trachoma-
endemic populations also give useful 
assistance in a few other countries: cooper-
ation with other community-based disease 
control programs should be considered.
How	should	the	dose	
of	azithromycin	be	
determined?
For trachoma control purposes, the 
recommended dose of azithromycin is one 
dose of 20mg of medicine per kilogram 
body weight, to a maximum of 1g. However, 
weighing scales are expensive to buy, 
bulky and heavy to transport, and are 
sometimes unreliable in the field. Height-
based azithromycin dosing11 12 13 is now 
accepted as an economical, safe, effective 
and convenient alternative. Since the 
relationship between height and weight 
varies from one population to the next, 
programme managers should not use generic 
height-based dosing scales, but rather 
ensure that the scale used is appropriate 
for the specific recipient population.
How	often	and	how	many	
times	should	azithromycin	
be	given?
At present, there are no good data 
demonstrating the relative effect of 
different frequencies of antibiotic distri-
bution. Computer simulations of the effect 
of antibiotics suggest that in areas where 
trachoma is moderately endemic, annual 
treatment should be undertaken, but that 
in hyperendemic areas (prevalence of 
TF in children >50 per cent), treatment 
every six months may be required.10 14 
Trials to test this hypothesis are currently 
in progress. In the meantime, antibiotics 
should be distributed every 12 months. 
Revised WHO guidelines suggest that, 
once a decision has been made to treat 
a district or a community with antibi-
otics, three annual distributions should 
be undertaken before reassessing the 
area as to the need to stop or continue.
What	impact	will	distribution	
of	azithromycin	have	on	
trachoma?
In a study village in Northern Tanzania, 94 per 
cent of 978 residents were given a single-
dose of azithromycin, and a further 4 per 
cent given tetracycline eye ointment. The 
prevalence of ocular C. trachomatis infection 
fell from 9.5 per cent before treatment to 
2.1 per cent two months afterwards, and 0.1 
per cent (only one resident infected) at two 
years.1 5 If these results could be replicated 
at national level by achieving high coverage 
with azithromycin throughout entire endemic 
districts, very rapid progress could be made 
towards global trachoma elimination.
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Height-based azithromycin dosing. EtHIoPIa
azithromycin tablets in the hand of a child. 
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Hyperendemic area – an area in which the particular 
disease or condition has a high prevalence
Hypoendemic area – an area in which the particular 
disease or condition has a low (but not zero) prevalence.
mass distribution (of antibiotics) - treatment of all 
members of all families in the community or district.
operational comparison – a comparison between 
different treatments made under operational 
conditions, such as in the context of a disease control 
programme. In the case of a comparison between the 
effectiveness of azithromycin and that of tetracycline, 
azithromycin would be directly-observed, and tetracy-
cline would be applied at home, unsupervised, by the 
patient or their parent.
Prevalence – the number of cases of a disease or 
condition that are present in a defined population at a 
particular point in time.
targeted distribution – treatment only of subsets of 
the community, as opposed to ‘mass distribution’. In 
trachoma, targeted distribution often refers to identifi-
cation and treatment of families in which there are one 
or more members with TF or TI, but other targeted distri-
bution strategies have also been used.
Glossary of terms
SAFE	STRATEGY	ANTIBIOTICS	Continued
Will	mass	distribution	
of	azithromycin	for	
trachoma	control	
promote	antibiotic	
resistance?
There is concern that annual mass distri-
bution of single-dose azithromycin will 
encourage the development of resistant 
strains of C. trachomatis or other 
pathogens. There are as yet no published 
data showing the effect of azithromycin on 
antibiotic resistance in ocular C. tracho-
matis isolates. Selection of antibiotic-
resistant conjunctival S. pneumoniae 
strains following azithromycin distribution 
has been identified, but the clinical signifi-
cance of this is unclear.16 Three published 
studies have examined the impact of 
azithromycin given for trachoma on 
nasopharyngeal S. pneumoniae. The first, 
in Australia, showed an increase in the 
prevalence of azithromycin resistance in 
S. pneumoniae from baseline to two
weeks after treatment; the prevalence 
of resistance fell between two weeks and 
two months, and again between two 
months and six months.17 However,
follow-up was incomplete, there was no 
control group, and background antibiotic 
use is likely to be higher in Australia than in 
most other trachoma-endemic areas. The 
second study, in Nepal, found resistant 
S. pneumoniae strains in only a very small 
proportion of children, all of whom had 
been given azithromycin on two separate 
occasions. This suggests that multiple 
rounds of azithromycin may be necessary to 
select for resistance in nasopharyngeal 
pneumococci.18 The third and largest study 
published to date was conducted in 
Tanzania. More than 1,200 children were 
swabbed at baseline, two months after 
treatment and six months after treatment; 
only one macrolide (azithromycin-like drug)-
resistant isolate was identified, six months 
after azithromycin distribution.19 Perhaps if 
background macrolide resistance is rare, 
mass distribution of azithromycin will have 
little impact on S. pneumoniae antibiotic 
sensitivities.
What	if	azithromycin	is	
not	available?
If azithromycin is not available to the 
programme in your district, the World Health 
Organization recommends community-
based distribution of tetracycline eye 
ointment using the same guidelines 
detailed above. However, the ease of 
use of azithromycin and the likelihood 
that recipients are more compliant with 
treatment, make it the first-line antibiotic 
for trachoma control: endemic countries 
are encouraged to consult the International 
Trachoma Initiative to find out whether 
donated azithromycin can be accessed 
by their national control programme.
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a mother treating her child with 1% tetracycline eye ointment. KENya
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